R&D
LSX World Congress – Day Two
On Day Two of 2024's LSX World Congress, we’ll hear about the biotech/biopharma IPO market, the 2024 US Presidential election, and about the future of digital health.
News
Moderna will cut $1.1bn off its annual R&D spend
Moderna is showcasing its R&D pipeline to investors today, but the headline news is a decision to cut its R&D spend by a massive $1.1 billion a year from 2027, reversing years of gr
News
GSK drops HSV jab, leaving rival mRNA shots in pole position
GSK has abandoned its clinical-stage vaccine for herpes simplex virus (HSV) after a disappointing phase 1/2 trial, ceding the ground to mRNA shots in development at Moderna and BioNTech.
News
Dupixent delivers in two skin disease trials
Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications f
R&D
Mpox is on the rise again as outbreak gathers pace
The original mpox outbreak began in 2022, but case numbers have rumbled on, despite countermeasures.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
